AMRI attributed a robust first quarter to its growing API business and recent acquisitions, and says to expect more M&A activity this year.
A new study is shaking up ideas about a known therapeutic strategy for Alzheimer’s disease, following a discovery by scientists at Scripps Research Institute testing enzyme inhibitors.
Capsugel says it is bolstering its service to offer specialised dry powder inhalation (DPI) formulations, allowing biotherapeutics to be delivered to the lung rather than by injection.
Schott, Heuft and GEA have teamed up to offer drugmakers a serialisation service for primary packaging to help with EU anti-counterfeiting requirements.
Inaccurate and incomplete information on excipients referenced in the US FDA Inactive Ingredient Database (IID), as well as other agency policies and guidance on the review of inactive ingredients in ANDAs (Abbreviated New Drug Applications) “continue to create confusion for the pharmaceutical industry,” according to a position paper from IPEC-Americas...
Persuading API manufacturers to seek prequalification is a challenge according to the WHO, which wants to raise awarness about the process and the positive impact it has on a suppliers' reputation.